Cargando…

Ranibizumab, Verteporfin Photodynamic Therapy or Observation for the Treatment of Myopic Choroidal Neovascularization: Cost Effectiveness in the UK

PURPOSE: The aim of this study was to evaluate the cost effectiveness of ranibizumab compared with verteporfin photodynamic therapy (vPDT) or no treatment (observation) in patients with visual impairment due to myopic choroidal neovascularization (CNV). METHODS: A Markov model with health states def...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claxton, Lindsay, Malcolm, Bill, Taylor, Matthew, Haig, Jennifer, Leteneux, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2014
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210643/ https://www.ncbi.nlm.nih.gov/pubmed/25300507 http://dx.doi.org/10.1007/s40266-014-0216-y

Ejemplares similares

RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study
por: Chen, Youxin, et al.
Publicado: (2019)

Single intravitreal ranibizumab for myopic choroidal neovascularization
por: Nor-Masniwati, Saidin, et al.
Publicado: (2011)

Photodynamic Therapy With Verteporfin for Choroidal Neovascularization in Patients with Angioid Streaks
por: Lee, Jun Mok, et al.
Publicado: (2007)

Photodynamic Therapy with Verteporfin for Corneal Neovascularization
por: Al-Torbak, Abdullah A.
Publicado: (2012)

Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
por: Karagiannis, Dimitrios, et al.
Publicado: (2017)

Verteporfin photodynamic therapy combined with intravitreal triamcinolone for choroidal neovascularization due to angioid streaks
por: Pece, Alfredo, et al.
Publicado: (2010)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore, Ron P, et al.
Publicado: (2017)

Verteporfin Photodynamic Therapy Combined with Intravitreal Ranibizumab for Polypoidal Choroidal Vasculopathy Controversy Concerning Long-Term Followup
por: Fernández, Maribel, et al.
Publicado: (2012)

Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial
por: Lim, Tock H., et al.
Publicado: (2020)

Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye
por: Stepanov, Alexandr, et al.
Publicado: (2020)

Treatment Satisfaction and Well-Being in Patients with Myopic Choroidal Neovascularization Treated with Ranibizumab in the REPAIR Study
por: Amoaku, Winfried M., et al.
Publicado: (2015)

VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION
por: Ceklic, Lala, et al.
Publicado: (2017)

Combined photodynamic therapy and intravitreal bevacizumab as treatment for nonresponsive myopic choroidal neovascularization
por: Chhablani, Jay Kumar
Publicado: (2010)

Combination therapy of low-fluence photodynamic therapy and intravitreal ranibizumab for choroidal neovascular membrane in choroidal osteoma
por: Morris, Rodney J, et al.
Publicado: (2011)

Long-term remission of myopic choroidal neovascular membrane after treatment with ranibizumab: a case report
por: Kumaran, Neruban, et al.
Publicado: (2009)

Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS study
por: Hamilton, Robin D., et al.
Publicado: (2020)

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study
por: Takahashi, Kanji, et al.
Publicado: (2018)

Choroidal Osteoma and Secondary Choroidal Neovascularization Treated with Ranibizumab
por: Sarıgül Sezenöz, Almila, et al.
Publicado: (2017)

LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY
por: Tan, Nikolle W., et al.
Publicado: (2018)

Choroidal thickness after intravitreal ranibizumab injections for choroidal neovascularization
por: Ellabban, Abdallah A, et al.
Publicado: (2012)

Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes
por: Gross, Nikolai, et al.
Publicado: (2013)

3-year follow-up of half-dose verteporfin photodynamic therapy for central serous chorioretinopathy with OCT-angiography detected choroidal neovascularization
por: Hu, Yu-Chen, et al.
Publicado: (2021)

Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study
por: Cha, Dong Min, et al.
Publicado: (2014)

Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results—A Retrospective, Comparative Study
por: Erden, Burak, et al.
Publicado: (2019)

Spectral domain-optical coherence tomography retinal biomarkers in choroidal neovascularization of multifocal choroiditis, myopic choroidal neovascularization, and idiopathic choroidal neovascularization
por: Gao, Rui, et al.
Publicado: (2021)

Association between choriocapillaris flow deficit and choroidal neovascularization activity in eyes with myopic choroidal neovascularization
por: Uematsu, Sato, et al.
Publicado: (2021)

A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration
por: Nowak, Michał S., et al.
Publicado: (2012)

Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia
por: Rishi, Pukhraj, et al.
Publicado: (2011)

Combined photodynamic therapy and intravitreal ranibizumab as treatment for extrafoveal choroidal neovascularization associated with age-related macular degeneration
por: Chhablani, Jay Kumar
Publicado: (2010)

Current and emerging treatment options for myopic choroidal neovascularization
por: El Matri, Leila, et al.
Publicado: (2015)

Multimodal imaging and diagnosis of myopic choroidal neovascularization in Caucasians
por: Milani, Paolo, et al.
Publicado: (2016)

Result of intravitreal aflibercept injection for myopic choroidal neovascularization
por: Chen, Shih-Lin, et al.
Publicado: (2021)

Indocyanine Green Angiographic Features of Myopic Subfoveal Choroidal Neovascularization as a Prognostic Factor after Photodynamic Therapy
por: Byeon, Suk Ho, et al.
Publicado: (2006)

Intravitreal ranibizumab for treatment of choroidal neovascularization secondary to a bilateral choroidal osteoma
por: Zafar, Sidra, et al.
Publicado: (2016)

Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan
por: Ohno-Matsui, Kyoko, et al.
Publicado: (2018)

A case of presumed choroidal metastasis from carcinoid tumor treated by photodynamic therapy with verteporfin
por: Kawakami, Setsuko, et al.
Publicado: (2013)

Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis
por: Shah, Nikunj J, et al.
Publicado: (2011)

Intravitreal ranibizumab for the treatment of choroidal neovascularization secondary to ocular toxoplasmosis
por: Pandey, Neeraj, et al.
Publicado: (2013)

Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration
por: Tsuchihashi, Takashi, et al.
Publicado: (2013)

Comparison of intravitreal bevacizumab and ranibizumab used for myopic choroidal neovascularization: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials
por: Hu, Qiuming, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pbpee809tatsjbgb05vhftgpmm